Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts
| Autor: | Adam J. Shuhendler, Andrew M. Rauth, Ping Cai, Preethy Prasad, Xiao Yu Wu |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Cancer Research
Combination therapy Mitomycin Mice Nude Breast Neoplasms Pharmacology Polyethylene Glycols Mice Random Allocation Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols Stearates medicine Animals Humans Neoplasm Doxorubicin Mammary tumor Liposome Chemistry Mitomycin C medicine.disease Lipids Xenograft Model Antitumor Assays Drug Resistance Multiple Multiple drug resistance Drug Combinations Oncology Drug Resistance Neoplasm Toxicity Nanoparticles Female medicine.drug |
| Zdroj: | Cancer Letters. 334:263-273 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2012.08.008 |
| Popis: | Multidrug resistance (MDR) and drug toxicity are two major factors responsible for the failure of cancer chemotherapy. Herein the efficacy and safety of combination therapy using doxorubicin (Dox, D)-mitomycin C (MMC, M) co-loaded stealth polymer-lipid hybrid nanoparticles (DMsPLNs) were evaluated in sensitive and MDR human mammary tumor xenografts. DMsPLN demonstrated enhanced efficacy compared to liposomal Dox (PLD) with up to a 3-fold increase in animal life span, a 10-20% tumor cure rate, undetectable normal tissue toxicity and decreased tumor angiogenesis. These results suggest DMsPLN have potential as an effective treatment of breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect